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Purpose: Combined treatment with alendronate and alfacalcidol is more useful to increase 
bone mineral density (BMD) than alendronate or alfacalcidol alone. A retrospective study 
was conducted to investigate the 3-year outcome of combined treatment with alendronate and 
alfacalcidol in patients with severe bone loss (BMD # 50% of the young adult mean) and 
osteoporotic fracture.
Methods: Thirty-four patients (six men and 28 postmenopausal women) with primary or 
secondary osteoporosis who had been treated with alendronate and alfacalcidol for more than 
3 years were analyzed. The lumbar spine or total hip BMD and bone turnover markers were 
monitored, and the incidence of osteoporotic fractures was assessed.
Results: The urinary level of cross-linked N-terminal telopeptides of type I collagen and 
serum level of alkaline phosphatase significantly decreased (−42.5% at 3 months and −18.9% 
at 3 years), and the lumbar spine BMD, but not the total hip BMD, significantly increased 
(14.8% at 3 years), compared with the baseline values. However, the incidence of vertebral 
and nonvertebral fractures was 26.5% and 2.9%, respectively, suggesting a high incidence of 
vertebral fractures.
Conclusion: The results of the present study suggest that combined treatment with alendronate 
and alfacalcidol may be useful to reduce bone turnover and increase the lumbar spine BMD in 
patients with severe bone loss and osteoporotic fracture. However, its efficacy against vertebral 
fractures appears not to be sufficient. Thus, anabolic agents such as teriparatide should be taken 
into consideration as first-line drugs in patients with severe osteoporosis.
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Introduction
Alendronate (ALN) is widely used for the treatment of postmenopausal, glucocorticoid-
induced, and male osteoporosis. The Fracture Intervention Trial demonstrated 
the   efficacy of ALN against vertebral, nonvertebral, hip, and wrist fractures in 
postmenopausal women with osteoporosis.1,2 Furthermore, a recent systematic 
review analyzing 11 randomized controlled trials (RCTs) representing 12,068 women 
  confirmed both clinically important and statistically significant reductions in vertebral, 
nonvertebral, hip, and wrist fractures for secondary prevention (gold-level evidence).3 
ALN has also been reported to reduce the incidence of vertebral fractures in patients 
treated with glucocorticoid or patients with male osteoporosis.4,5Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The incidence of vertebral fractures is higher and that of 
hip fractures is lower among elderly Japanese people than 
among elderly Western people.6 ALN is regarded as a first-
line drug for the treatment of postmenopausal osteoporosis in 
Japan, because RCTs in postmenopausal Japanese women with 
osteoporosis revealed that ALN treatment (1–3 years) suppressed 
bone turnover, increased the bone mineral density (BMD), and 
reduced the incidence of vertebral fractures.7–10 RCTs in Japanese 
patients treated with glucocorticoid showed that ALN treatment 
(1–2 years) sustained or increased the lumbar spine BMD.11–13 
Furthermore, a RCT in Japanese men with osteoporosis or 
osteopenia and clinical risk factors of fractures confirmed 
that ALN treatment (1 year) increased the total hip BMD.14
In Japan, patients are diagnosed as having osteoporosis 
according to the Japanese diagnostic criteria.15,16 Namely, 
patients with a BMD , 70% of young adult mean (YAM) or 
70%–80% of YAM along with a history of osteoporotic fractures 
were diagnosed as having osteoporosis. We have confirmed the 
long-term (4–7 years) efficacy and safety of ALN treatment in 
postmenopausal Japanese women or men with osteoporosis 
or osteopenia and clinical risk factors of fractures.17–19 In 
our clinical practice, however, patients with severe bone loss 
(BMD # 50% of YAM) are not common, and the effects of 
ALN treatment on BMD, bone turnover markers, and fracture 
incidence remain to be established in such patients.
The AAC-Trial demonstrated that combined treatment with 
ALN and alfacalcidol (ALF) exhibited superiority in terms of 
BMD, overall fractures, rate of falls, and back pain over either 
ALN in combination with plain vitamin D or ALF alone in 
established postmenopausal or male osteoporosis.20 An RCT 
conducted by Felsenberg et al21 revealed that ALF increased 
the efficacy of ALN treatment in osteopenic/osteoporotic 
postmenopausal women on spine BMD, cortical and trabecular 
BMD of the tibia, and bending stiffness of the tibia. This 
line of evidence suggests the beneficial effect of combined 
treatment with ALN and ALF in patients with osteoporosis. 
A retrospective study was conducted to investigate the 3-year 
outcome of combined treatment with ALN and ALF in patients 
with severe bone loss (BMD # 50% of YAM) and osteoporotic 
fracture. The incidences of osteoporotic fractures, including 
morphometric vertebral fractures and clinical vertebral and 
nonvertebral (hip, distal radius, and proximal humerus) 
fractures, were also assessed.
Subjects and methods
subjects
Thirty-four Japanese patients who had been treated with ALN 
and ALF for more than 3 years were recruited at the outpatient 
clinic of Keiyu Orthopaedic Hospital (Gunma, Japan) during 
the 3-month period between January 4 and April 4, 2011. The 
inclusion criteria were primary or secondary osteoporosis, 
patients with severe bone loss (BMD # 50% of YAM) and 
osteoporotic vertebral, hip, distal radius, or proximal humerus 
fracture at the start of treatment. The exclusion criteria were 
histories of reflux esophagitis, gastric or duodenal ulcer, and 
renal failure.
The assessment prior to combined treatment with ALN 
and ALF included a medical history, physical examination, 
plain X-rays of the thoracic and lumbar spine, lumbar spine 
or total hip BMD measurement, and blood and urinary 
biochemical tests including serum calcium, phosphorus, 
and alkaline phosphatase (ALP), and urinary cross-linked 
N-terminal telopeptides of type I collagen (NTX). The serum 
calcium, phosphorus, and ALP levels were measured using 
the standard laboratory technique, and the urinary NTX levels 
were measured using enzyme-linked immunosorbent assay. 
The lumbar spine or total hip BMD was measured using dual-
energy X-ray absorptiometry (DXA) as described below.
The patients had been treated with ALN (5 mg daily or 
35 mg weekly) plus ALF (1 µg daily). The doses indicated 
in the parentheses above are the doses used in Japan for the 
treatment of postmenopausal women with osteoporosis and 
have been recognized as being safe and effective.7–10,22 Daily 
ALN was available throughout the study period, but weekly 
ALN only became available after October 2006. All the 
patients had been treated with daily ALN and then switched to 
weekly ALN just after October 2006. The effects of daily and 
weekly ALN on the BMD and bone turnover markers as well 
as the incidence of side effects were reported to be similar in 
postmenopausal Japanese women with osteoporosis.10
The urinary levels of NTX were measured at 3 months 
after the start of treatment, based on the results of our 
previous study.23 A urinary NTX measurement performed 
3 months after the start of ALN treatment provides impor-
tant information and is sufficient to monitor the effects of 
treatment for osteoporosis.23 The serum levels of calcium, 
phosphorus, and ALP and the lumbar spine or total hip BMD 
were measured every 6 months after the start of treatment. 
The outcome of combined treatment with ALN and ALF for 
3 years was evaluated. The present study was approved by 
the Ethics Committee of Keiyu Orthopaedic Hospital.
Assessment of morphometric  
vertebral fractures
Plain lateral X-ray films of the thoracic and lumbar spine 
were obtained at baseline to detect evidence of morphometric Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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vertebral fractures. According to the Japanese criteria, 
a   vertebral fracture was defined according to the vertebral 
height on lateral X-ray films.15,16 Briefly, the vertebral height 
was measured at the anterior (A), central (C), and posterior 
(P) parts of the vertebral body, and the presence of a vertebral 
fracture was confirmed when (1) a reduction in the vertebral 
height of more than 20% (A, C, and P) compared with the 
height of the adjacent vertebrae was observed, (2) the C/A 
or C/P was less than 0.8, or (3) the A/P was less than 0.75. 
The assessment for vertebral fractures was performed at the 
T4–L4 level.
Assessment of clinical vertebral  
and nonvertebral fractures
Low-traumatic osteoporotic clinical fractures were assessed. 
Clinical vertebral fractures were determined based on clinical 
symptoms and radiographs or magnetic resonance images 
of the lumbar and thoracic spine. Nonvertebral fractures in 
terms of osteoporotic fractures at the distal radius,   proximal 
humerus, and hip, were determined based on clinical 
symptoms and radiographs of the wrist, shoulder, and hip 
joints, respectively.
Measurement of lumbar spine  
or total hip BMD
The BMD of the lumbar spine or total hip in the antero-
posterior view was measured using DXA with a Hologic 
QDR 1500W apparatus (Hologic Inc, Bedford, MA). 
The coefficient of variation of five measurements with 
repositioning within 72 hours each time was less than 1.2% 
in three persons. Primarily, the lumbar spine (L1–L4) was 
chosen as a skeletal site for BMD measurement. However, 
the first lumbar vertebra (L1) was omitted for patients whose 
lumbar spine radiographs showed callus formation after L1 
vertebral fracture. In this case, the lumbar spine (L2–L4) 
BMD was adopted. The total hip BMD was measured for 
patients whose lumbar spine radiographs showed severe 
spondylosis, severe scoliosis, callus formation after L2, 
L3, or L4 vertebral fracture, or severe aortic calcification. 
The lumbar spine BMD was measured for 30 patients, 
and the total hip BMD for four patients (two men and two 
postmenopausal women).
statistical analysis
Data were expressed as the mean ± standard deviation. 
A one-way analysis of variance (ANOVA) with repeated 
measurements was used to determine the significance of 
longitudinal changes in the BMD and biochemical markers. 
A two-way ANOVA with repeated measurements was used to 
compare longitudinal changes in the BMD and biochemical 
markers between men and postmenopausal women. A Fisher’s 
exact test was used to compare the incidence of fractures 
between men and postmenopausal women. All the statistical 
analyses were performed using the Stat View-J5.0 (Abacus 
Concepts Inc, Berkeley, CA) program on a Windows® com-
puter. A significance level of P , 0.05 was used for all the 
comparisons.
Results
Characteristics of the study subjects  
at the start of treatment
Six patients were men and 28 patients were postmenopausal 
women. Twelve patients had diseases that might affect bone 
metabolism: glucocorticoid use due to asthma or subacute 
thyroiditis (n = 4), hyperthyroidism (n = 2), gastrectomy 
(n = 2), breast cancer-induced bone loss due to aromatase 
inhibitors (n = 1), warfarin used after valve transplantation 
of the heart (n = 1), osteogenesis imperfecta (n = 1), and 
  Parkinson’s disease (n = 1). Table 1 shows the characteristics 
of the study subjects at the start of the treatment. The mean 
age of all the subjects was 67.4 years (range: 41–80 years). 
The mean percentage of the YAM in the lumbar spine and 
total hip BMD was 45.8% and 43.8%, respectively. The 
mean levels of serum calcium, phosphorus, and ALP were 
Table  1  Characteristics  of  study  subjects  at  the  start  of 
treatment
Characteristic Value
gender (male/female) 6/28
Age (years) 67.4 ± 9.5 (41–80)
height (m) 1.50 ± 0.10 (1.31–1.77)
Body weight (kg) 45.8 ± 8.8 (35–68)
Body mass index (kg/m2) 20.3 ± 2.2 (16.8–26.7)
Lumbar spine BMD (g/cm2) 0.464 ± 0.042 (0.323–0.511)
%YAM of lumbar spine BMD (%) 45.8 ± 4.0 (33–50)
Total hip BMD (g/cm2) 0.395 ± 0.071 (0.293–0.450)
%YAM of total hip BMD (%) 43.8 ± 5.2 (36–47)
serum calcium (mg/dL) 9.4 ± 0.4 (8.7–10.2)
serum phosphorus (mg/dL) 3.2 ± 0.4 (2.4–4.0)
serum ALP (IU/L) 297 ± 113 (133–532)
Urinary nTX (nmol BCe/mmol Cr) 84.9 ± 39.4 (42.8–205.3)
number (%) of patients with prevalent 
vertebral fractures
30 (88.2%)
number (%) of patients with history of 
non-vertebral fractures
6 (17.6%)
Notes: Data are expressed as means ± sD. numbers in the parenthesis of the right 
column are ranges.
Abbreviations: BMD, bone mineral density; YAM, young adult mean; ALP, alkaline 
phosphatase; nTX, cross linked n-terminal telopeptides of type I collagen; BCe, 
bone collagen equivalent; Cr, creatinine.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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within the normal ranges (8.4–10.2 mg/dL, 2.5–4.5 mg/dL, 
and 100–340 IU/L, respectively). The mean level of   urinary 
NTX was higher than the normal range for Japanese women 
(9.3–54.3 nmol BCE/mmol Cr),24 indicating a high turnover 
characteristic of osteoporosis. All patients had osteoporotic 
vertebral or nonvertebral (hip, distal radius, and proximal 
humerus) fractures. The number of women with prevalent 
vertebral fractures was 30 (88.2%), and the number of patients 
with a history of nonvertebral fractures was six (17.6%).
Changes in lumbar spine and total  
hip BMD
Figure 1 shows that the lumbar spine BMD continued to 
increase for 3 years. A one-way ANOVA with repeated mea-
surements showed significant longitudinal changes in the 
lumbar spine BMD (P , 0.0001). The mean rates of change in 
the lumbar spine BMD after 1, 2, and 3 years of treatment were 
+11.3%, +12.4%, and +14.8%, respectively. However, total 
hip BMD did not change significantly (P = 0.8706). The mean 
rates of change in the total hip BMD after 1, 2, and 3 years 
of treatment were −0.5%, +3.2%, and +6.4%, respectively.
A two-way ANOVA with repeated measurements showed 
that longitudinal changes in the BMD did not differ signifi-
cantly between men and postmenopausal women (P = 0.8423 
for the lumbar spine and P = 0.1971 for the total hip).
Changes in biochemical markers
Figure 2 shows the changes in the biochemical markers. 
The mean urinary NTX level decreased to the normal range 
(g/cm2)
(month)
0.25
0.35
0.45
0.55
0.65
0612 18 24 30 36
Lumbar spine 
Total hip 
Figure 1 Changes in lumbar spine and total hip BMD.
Notes: Data are expressed as the mean ± sD. A one-way AnOVA with repeated 
measurements showed significant longitudinal changes in the lumbar spine BMD 
(P , 0.0001). The mean rates of change in the lumbar spine BMD after 1, 2, and 3 
years of treatment were +11.3%, +12.4%, and +14.8%, respectively. however, total 
hip BMD did not change significantly (P = 0.8706). The mean rates of change in the 
total hip BMD after 1, 2, and 3 years of treatment were −0.5%, +3.2%, and +6.4%, 
respectively. 
Abbreviations: AnOVA, analysis of variance; BMD, bone mineral density.
for Japanese women (9.3–54.3 nmol BCE/mmol Cr)24 
after 3 months of treatment, and the mean serum ALP 
level decreased but remained within the normal range 
(135–310 IU/L) during the 3-year period. A one-way ANOVA 
with repeated measurements showed significant longitudinal 
changes in the serum ALP and urinary NTX levels (both 
P , 0.0001). The mean rates of change in the urinary NTX 
level after 3 months of treatment were −42.5%. The mean 
rates of change in the serum ALP level after 1, 2, and 3 years 
of treatment were −26.1%, −20.5%, and −18.9%, respectively. 
However, the serum calcium and phosphorus levels did not 
change significantly (P = 0.0760 and 0.8799, respectively).
A two-way ANOVA with repeated measurements showed 
that longitudinal changes in the serum calcium, phosphorus, 
and ALP and urinary NTX levels did not differ significantly 
between men and postmenopausal women (P = 0.1832 for 
calcium, P = 0.9447 for phosphorus, P = 0.3251 for ALP, 
and P = 0.4121 for urinary NTX).
Incidence of osteoporotic fractures
Table 2 shows that during the 3-year treatment period, 
nine patients (26.5%) experienced vertebral fractures 
(morphometric fractures in seven patients [20.6%] and 
clinical fractures in two patients [5.9%]). One patient 
(2.9%) experienced nonvertebral fracture (proximal humerus 
fracture).
A Fisher’s exact test showed that the incidence of fractures 
did not differ significantly between men and postmenopausal 
women (16.7% for men and 32.1% for postmenopausal 
women, P = 0.4502).
Adverse events
No serious adverse events, including osteonecrosis of the jaw, 
femoral diaphysis atypical fractures, and atrial fibrillation,25–35 
were observed.
Discussion
Combined treatment with ALN and ALF increased the 
lumbar spine BMD (+11.3%, +12.4%, and +14.8% at 1, 2, 
and 3 years, respectively) subsequent to reductions in the 
urinary NTX level (−42.5% at 3 months) and the serum ALP 
level (−26.1%, −20.5%, and −18.9% at 1, 2, and 3 years, 
respectively). RCTs have shown that ALN treatment (5 mg 
daily or 35 mg weekly) decreases the urinary NTX (−45% 
at 3 months) and serum ALP (about −20% at 3 years) levels 
and increases the lumbar spine BMD (+9.2% at 3 years) 
in postmenopausal Japanese women with osteoporosis.8,10 
Our previous two studies also showed that ALN treatment Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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in postmenopausal women with osteoporosis and men with 
osteoporosis increased the lumbar spine BMD (+5.8% at 
1 year and +9.4% at 3 years, respectively) subsequent to 
reductions in the urinary NTX level (−39.2% and −40.0%, 
respectively, at 3 months) and the serum ALP level (−17.8% 
at 1 year and −21.2% at 3 years, respectively).36,37 On the 
other hand, an RCT showed that ALF mildly increased the 
lumbar spine BMD (1.35% at 1 year) without significantly 
influencing bone turnover markers in postmenopausal 
women with osteoporosis.9 The increase in the lumbar 
spine BMD in the present study appears to be greater than 
those in the previous studies regarding ALN treatment, 
despite the similar reductions in bone turnover markers, 
suggesting the additive effect of ALN and ALF on the 
lumbar spine BMD.
The results of the Fracture Intervention Trial revealed that 
ALN effectively reduced the fracture risk in postmenopausal 
women with vertebral fractures and low BMD, including 
those women at the highest risk because of advanced age or 
severe osteoporosis.38 Although the relative risk for vertebral 
fracture was compared between age ,75 years and $75 years, 
femoral neck BMD , 0.59 g/cm2 and $0.59 g/cm2, one exist-
ing vertebral fracture and $2 existing vertebral fractures, 
or history of postmenopausal fracture and no history of 
postmenopausal fracture in this analysis, the incidence of 
vertebral fractures after ALN treatment was not compared 
among groups.
The incidence of vertebral fractures was 26.5% (mor-
phometric fracture 20.6% and clinical fracture 5.9%) in 
patients (mean age: 67.8 years) with severe bone loss 
(100% with a history of osteoporotic fracture). Our previ-
ous study revealed that the incidence of vertebral fractures 
after 3-year ALN treatment was 13.3% (morphometric 
fracture 9.6% and clinical fracture 3.7%) in postmeno-
pausal women (mean age: 67.4%) with osteoporosis (37% 
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Figure 2 Changes in biochemical markers. 
Notes: Data are expressed as the mean ± SD. A one-way ANOVA with repeated measurements showed significant longitudinal changes in the serum ALP and urinary 
nTX levels (both P , 0.0001). The mean rates of change in the urinary nTX levels after 3 months of treatment were −42.5%. The mean rates of change in the serum ALP 
levels after 1, 2, and 3 years of treatment were −26.1%, −20.5%, and −18.9%, respectively. However, the serum calcium and phosphorus levels did not change significantly 
(P = 0.0760 and 0.8799, respectively). 
Abbreviations: AnOVA, analysis of variance; ALP, alkaline phosphatase; nTX, cross linked n-terminal telopeptides of type I collagen; BCe, bone collagen equivalent;   
Cr, creatinine.
Table 2 Incidence of vertebral and nonvertebral fractures
Fracture Incidence n (%)
Vertebral
Morphometric 7 (20.6%)
Clinical 2 (5.9%)
Nonvertebral
hip 0 (0.0%)
Distal radius 0 (0.0%)
Proximal humerus 1 (2.9%)Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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with a history of osteoporotic fracture).36 Thus, despite the 
greater increase in the lumbar spine BMD, the incidence of 
vertebral fractures was considered to be higher in patients 
with severe bone loss and osteoporotic fracture than those 
with postmenopausal osteoporosis. This result suggests 
the importance of BMD and preexisting osteoporotic 
fractures at baseline in the prevention of vertebral frac-
tures by bisphosphonate treatment. Shiraki et al39 reported 
that traditional risk factors such as older age, low BMD, 
and preexisting osteoporotic fractures were recognized as 
risks for incident fractures in postmenopausal osteoporo-
tic women treated with bisphosphonates, supporting our 
suggestion. Thus, anabolic agents, such as teriparatide, 
which are able to vigorously increase lumbar spine BMD40 
should be considered as the first-line drugs in the treatment 
of severe osteoporosis.
The total hip BMD did not change significantly from 
the baseline values in four patients (two men and two 
postmenopausal women). Our previous study showed that 
1-year treatment with ALN increased the total hip BMD 
by 2.3% from the baseline values in men with osteopo-
rosis or osteopenia and clinical risk factors of fractures.14 
However, the effect of ALN on total hip BMD has been 
less established in postmenopausal Japanese women with 
osteoporosis. In the present study, the mean rates of change 
in total hip BMD after 1, 2, and 3 years of treatment were 
−0.5%, +3.2%, and +6.4%, respectively, which was not 
statistically significant. This result may be attributable to the 
small sample size. Further studies are needed to establish 
the effect of ALN treatment with or without ALF on the 
total hip BMD in men and postmenopausal women with 
osteoporosis in Japan.
A couple of German studies showed that combined 
treatment with ALN and ALF improved physical function 
(chair rising time and time up and go) and back pain in elderly 
patients with a high risk of falls and fractures.41,42 Although 
we did not assess the risk of falls and back pain, it would be 
of interest to investigate the effect of combined treatment with 
ALN and ALF on fall incidence and subsequent fractures in 
frail patients with severe osteoporosis.
An epidemiological study has indicated that the inci-
dence of vertebral fractures is higher and that of hip frac-
tures is lower among elderly Japanese people than among 
elderly Western people.6 In the present study, no patients 
suffered from distal radius or hip fractures, although the 
incidence of vertebral fractures was considered to be high. 
Vitamin D supplementation is linked to a decreased risk of 
falls in ambulatory and institutionalized elderly patients, 
because muscle tissue has highly specific nuclear receptors 
for 1,25-dihydroxyvitamin D.43 Bischoff-Ferrari et al.44,45 
have shown that vitamin D supplementation appears to 
reduce the risk of falls and hip and any non-vertebral frac-
tures in ambulatory or institutionalized elderly persons. 
Thus, ALF might have played a significant role in reducing 
the risk of falls and subsequent fractures in the present 
study.
There is a notable limitation. Because the present 
study was a retrospective study with a small sample size, 
the results might be biased. RCTs are needed to confirm the 
effect of combined treatment with ALN and ALF on severe 
osteoporosis.
In conclusion, the present retrospective study showed 
that combined treatment with ALN and ALF suppressed 
bone turnover and increased lumbar spine BMD, compared 
with baseline values, over the course of a 3-year treatment 
period without causing any severe adverse events in patients 
with severe bone loss and osteoporotic fracture. However, 
its efficacy against vertebral fractures may not be sufficient. 
Thus, anabolic agents such as teriparatide should be taken 
into consideration as first-line drugs in patients with severe 
osteoporosis.
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